This platform significantly enhances the ionization efficiency and response intensity of target compounds—particularly trace and poorly ionizable substances—in LC-MS/MS analyses by employing a customized derivatization reaction system, while also optimizing their chromatographic retention behavior. By effectively addressing complex matrix interferences, it enables highly sensitive and selective quantitative analysis, making it an essential tool for overcoming the challenges associated with detecting low-abundance compounds.

Leveraging a diverse range of solid-phase extraction (SPE) sorbents—such as HLB, ion exchange, and others—and advanced automation technologies, we precisely eliminate complex interfering matrices from biological samples (e.g., plasma, tissues). This process enables highly efficient purification and enrichment of target analytes, significantly enhancing the signal-to-noise ratio and accuracy of subsequent analyses, thereby establishing a robust foundation for trace-level drug and metabolite research.

Addressing the challenges of peptide drugs—such as their tendency to adsorb and inherent instability—the platform features a dedicated sample-handling workflow, optimized chromatographic conditions (including specialized columns and mobile phases), and highly sensitive LC-MS/MS methods. These advancements effectively mitigate non-specific adsorption, enabling stable and precise quantification of peptide drugs in complex biological matrices, thereby supporting PK/PD studies as well as biomarker research.

Leveraging cutting-edge LC-MS/MS technology and a complementary kit, the platform enables precise analysis—either simultaneously or individually—of key components in antibody-drug conjugates (ADCs): the antibody, small-molecule payload, and linker. This ensures accurate quantification of ADC concentrations in biological samples, providing critical data to support drug development and evaluation.

Leveraging specialized separation techniques such as ultrafiltration, dialysis, and SPE, the platform precisely distinguishes and quantifies the levels of free versus entrapped drug content in liposomal formulations. Key metrics—including encapsulation efficiency, drug loading, and in vitro release behavior—are accurately measured, ensuring robust support for optimizing liposomal formulation processes, enhancing quality control, and facilitating in vitro-in vivo correlation studies.

To address the unique physicochemical properties of small nucleic acid drugs such as siRNA and ASO—namely their strong polarity and susceptibility to degradation—as well as complex biological matrix interference, the platform employs a proprietary sample pre-processing method, ion-pair reagents, specialized chromatographic columns, and highly sensitive LC-MS/MS technology, enabling stable, specific, and ultra-sensitive quantitative analysis of these compounds in biological samples.

Leveraging advanced separation technologies such as SEC and AF4, combined with highly sensitive detection methods like LC-MS/MS and ELISA, the platform can effectively separate and quantitatively analyze both protein-bound free drugs and unbound free drugs within protein nanoparticles (e.g., albumin nanoparticles). This capability provides critical analytical support for studying drug-loading efficiency, stability, and release characteristics of nanoparticle-based drug delivery systems.

The platform leverages the principles of enzymatic reaction kinetics, employing highly sensitive detection technologies—such as fluorescence and mass spectrometry—to monitor in real time the rate of substrate consumption or product formation. This enables precise qualitative and quantitative analysis of specific enzyme activities, supporting diverse applications including enzyme inhibitor screening, enzyme kinetic studies, clinical diagnostics, and functional assessments of drug-metabolizing enzymes.